BTIG Reiterates Buy on Nurix Therapeutics, Maintains $30 Price Target
Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc. NRIX | 0.00 |
BTIG analyst Jeet Mukherjee reiterates Nurix Therapeutics (NASDAQ:
NRIX) with a Buy and maintains $30 price target.
